1135282-93-7Relevant articles and documents
PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY
-
Page/Page column 56, (2021/10/22)
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I), Formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control
Aronov, Alex M.,Qing, Tang,Martinez-Botella, Gabriel,Bemis, Guy W.,Cao, Jingrong,Chen, Guanjing,Ewing, Nigel P.,Ford, Pamella J.,Germann, Ursula A.,Green, Jeremy,Hale, Michael R.,Jacobs, Marc,Janetka, James W.,Maltais, Francois,Markland, William,Namchuk, Mark N.,Nanthakumar, Suganthini,Poondru, Srinivasu,Straub, Judy,Ter Haar, Ernst,Xiaoling, Xie
experimental part, p. 6362 - 6368 (2010/03/31)
The Ras/Raf/MEK/ERK signal transduction, an oncogenic pathway implicated in a variety of human cancers, is a key target in anticancer drug design. A novel series of pyrimidylpyrrole ERK inhibitors has been identified. Discovery of a conformational change